These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35914546)

  • 1. Analytical and Preformulation Characterization Studies of Human Papillomavirus Virus-Like Particles to Enable Quadrivalent Multi-Dose Vaccine Formulation Development.
    Jerajani K; Wan Y; Hickey JM; Kumru OS; Sharma N; Pullagurla SR; Ogun O; Mapari S; Whitaker N; Brendle S; Christensen ND; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Joshi SB; Volkin DB
    J Pharm Sci; 2022 Nov; 111(11):2983-2997. PubMed ID: 35914546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part II- Real-time and Accelerated Stability Studies.
    Sharma N; Jerajani K; Wan Y; Kumru OS; Pullagurla SR; Ogun O; Mapari S; Brendle S; Christensen ND; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Volkin DB; Joshi SB
    J Pharm Sci; 2023 Feb; 112(2):458-470. PubMed ID: 36462710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative Combinations.
    Jerajani K; Wan Y; Kumru OS; Pullagurla SR; Kumar P; Sharma N; Ogun O; Mapari S; Brendle S; Christensen ND; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Joshi SB; Volkin DB
    J Pharm Sci; 2023 Feb; 112(2):446-457. PubMed ID: 36096284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylparaben as a preservative in the development of a multi-dose HPV-2 vaccine.
    Miao C; Ma X; Fan J; Shi L; Wei J
    Hum Vaccin Immunother; 2022 Nov; 18(5):2067421. PubMed ID: 35471842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.
    Valencia SM; Zacharia A; Marin A; Matthews RL; Wu CK; Myers B; Sanders C; Difilippantonio S; Kirnbauer R; Roden RB; Pinto LA; Shoemaker RH; Andrianov AK; Marshall JD
    Hum Vaccin Immunother; 2021 Aug; 17(8):2748-2761. PubMed ID: 33573433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Aluminum Adjuvant and Preservatives on Structural Integrity and Physicochemical Stability Profiles of Three Recombinant Subunit Rotavirus Vaccine Antigens.
    Agarwal S; Hickey JM; McAdams D; White JA; Sitrin R; Khandke L; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):476-487. PubMed ID: 31589875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combined LC-MS and Immunoassay Approach to Characterize Preservative-Induced Destabilization of Human Papillomavirus Virus-like Particles Adsorbed to an Aluminum-Salt Adjuvant.
    Caringal RT; Hickey JM; Sharma N; Jerajani K; Bewaji O; Brendle S; Christensen N; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Joshi SB; Volkin DB
    Vaccines (Basel); 2024 May; 12(6):. PubMed ID: 38932309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quantitative analysis of nine types of virus-like particles in human papilloma virus bulk by size-exclusion chromatography].
    Long Z; Li X; Li X; Liu J; Nie J; Li C; Li Y; Huang T; Huang W
    Se Pu; 2021 Apr; 39(4):424-429. PubMed ID: 34227763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
    Zhao Q; Modis Y; High K; Towne V; Meng Y; Wang Y; Alexandroff J; Brown M; Carragher B; Potter CS; Abraham D; Wohlpart D; Kosinski M; Washabaugh MW; Sitrin RD
    Virol J; 2012 Feb; 9():52. PubMed ID: 22356831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
    Park MH; You JW; Kim HJ; Kim HJ
    J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
    McKeage K; Romanowski B
    Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).
    McKeage K; Romanowski B
    BioDrugs; 2011 Aug; 25(4):265-9. PubMed ID: 21815703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of Aluminum-adjuvanted Recombinant P[4] Protein Antigen With Preservatives: Storage Stability and Backbone Flexibility Studies.
    Sawant N; Joshi SB; Weis DD; Volkin DB
    J Pharm Sci; 2022 Apr; 111(4):970-981. PubMed ID: 34758340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.